Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Sep. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Frank Torti [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On August 13, 2026, Dr. Frank Torti, President and Vant Chair of our subsidiary Roivant Sciences, Inc., entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 5,583,448 common shares held by Dr. Torti between November 12, 2026 and June 20, 2027.
|
| Name | Frank Torti, |
| Title | President and Vant Chair |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | August 13, 2026 |
| Expiration Date | June 20, 2027 |
| Arrangement Duration | 220 days |
| Aggregate Available | 5,583,448 |